Related coverage linked through entity extraction aliases.
Aug 06, 2026
Cocrystal Pharma advanced CDI-988 in a Phase 1b norovirus study and received FDA Fast Track designation. Nuvation Bio reported $18.5 million in IBTROZI net product revenues and presented updated TRUST trial data. Nautilus Biotechnology progressed its proteomics platform toward commercialization, maintaining a cash runway through 2027.
May 12, 2026
A review in Genes & Diseases says robust non-clinical safety assessment is critical for CRISPR-based gene therapies. It highlights genotoxic, delivery, and immunological risks and recommends risk-based development programs.
Apr 21, 2026
Wafik S. El-Deiry highlighted p53 research and the August 2025 approval of dordaviprone/modeyso, the first treatment for diffuse gliomas with H3K27M mutations. Separate posts also described glioblastoma precision oncology discussions and a lifetime achievement award in Mumbai.
Mar 24, 2026
Elicio Therapeutics granted inducement stock options to new employees, with one grant of 1,600 options at $12.16 per share and another of 30,300 options at $8.59 per share. The clinical-stage biotech company is developing novel immunotherapies targeting mKRAS-positive cancers, with its ELI-002 program showing promising Phase 1 results including 16.3-month median recurrence-free survival.
Mar 20, 2026
DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.
Feb 22, 2026
Patients with p53 aberrant or 17p deleted chronic lymphocytic leukemia face a more aggressive disease course requiring specialized treatment approaches including clinical trial enrollment and referral to high-volume centers.
Feb 26, 2026
Early trial of Rezatapopt shows 20% response rate in advanced cancers with p53 mutations, while researchers identify AMD3100 as potential solution to enable immunotherapy in rare liver cancer.
Feb 13, 2026
A case report published in Oncotarget details a 38-year-old woman who developed acute lymphoblastic leukemia and lymphoblastic lymphoma shortly after receiving her second Pfizer-BioNTech mRNA vaccine dose, prompting calls for further investigation into potential immune-related mechanisms.
